Resistance Oncology ApS: Financial statements 2019
CVR: 36945125
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 13,935 and a net result of DKK 9,885 compared with DKK -12,643 the year before. Equity in the 2019 report amounted to DKK -14,912.
- Gross Profit
- DKK 13,935
- Profit/Loss
- DKK 9,885
- Equity
- DKK -14,912
- Total Assets
- DKK 7,903
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 14 t. | 10 t. | -15 t. | - |
| 2018 | - | -15 t. | -13 t. | -25 t. | - |
| 2017 | - | 51 t. | 1.1 mio. | -12 t. | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Resistance Oncology ApS has published its annual report for 2018. Gross profit came to DKK -14,500, and the net result was DKK -12,643.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.